Literature DB >> 24705033

Urinary CXCL10: a marker of nephritis in lupus patients.

M A Marie1, R E Abu Khalil, H M Habib.   

Abstract

Systemic lupus erythematosus (SLE) is a connective tissue disease characterized by the formation of autoantibodies and immune complexes. Lupus nephritis is one of the hallmark features of SLE. CXCL10 is a chemokine secreted by IFNg- stimulated endothelial cells and has been shown to be involved in the pathological processes of autoimmune diseases. The objective was to measure urinary CXCL10 in SLE patients, to compare levels between nephritis and non-nephritis groups and to study its correlation with other variables. Sixty lupus patients were enrolled in our trial. Thirty patients had lupus nephritis and the other 30 were without evidence of lupus nephritis. Thirty healthy subjects were willing to participate as a healthy control group. Renal biopsy was performed for lupus nephritis group. Urinary CXCL10 was measured using the ELISA technique. Serum creatinine, C3, C4 and 24 h urinary proteins were measured. Lupus activity was assessed using systemic lupus erythematosus disease activity index (SLEDAI) scoring system. Renal activity was measured using renal activity scoring system. CXCL10 was significantly higher in lupus nephritis patients than in lupus patients without nephritis. CXCL10 was significantly correlated with renal activity score, 24 hours urinary proteins and the SLEDAI score. It is highly valid predictor of SLE nephritis with high sensitivity and specificity. CXCL 10 a highly sensitive and specific non-invasive diagnostic tool for lupus nephritis patients.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24705033     DOI: 10.4081/reumatismo.2013.719

Source DB:  PubMed          Journal:  Reumatismo        ISSN: 0048-7449


  9 in total

Review 1.  The Most Promising Biomarkers of Allogeneic Kidney Transplant Rejection.

Authors:  Karolina Rogulska; Iwona Wojciechowska-Koszko; Barbara Dołęgowska; Ewa Kwiatkowska; Paulina Roszkowska; Patrycja Kapczuk; Danuta Kosik-Bogacka
Journal:  J Immunol Res       Date:  2022-05-28       Impact factor: 4.493

Review 2.  Chemokines and Chemokine Receptors in the Development of Lupus Nephritis.

Authors:  Xiaofeng Liao; Tharshikha Pirapakaran; Xin M Luo
Journal:  Mediators Inflamm       Date:  2016-06-14       Impact factor: 4.711

3.  A Novel Multi-Biomarker Assay for Non-Invasive Quantitative Monitoring of Kidney Injury.

Authors:  Drew Watson; Joshua Y C Yang; Reuben D Sarwal; Tara K Sigdel; Juliane M Liberto; Izabella Damm; Victoria Louie; Shristi Sigdel; Devon Livingstone; Katherine Soh; Arjun Chakraborty; Michael Liang; Pei-Chen Lin; Minnie M Sarwal
Journal:  J Clin Med       Date:  2019-04-12       Impact factor: 4.241

4.  Interferon-Inducible Protein 10 and Disease Activity in Systemic Lupus Erythematosus and Lupus Nephritis: A Systematic Review and Meta-Analysis.

Authors:  Pongpratch Puapatanakul; Sonchai Chansritrakul; Paweena Susantitaphong; Thornthun Ueaphongsukkit; Somchai Eiam-Ong; Kearkiat Praditpornsilpa; Wonngarm Kittanamongkolchai; Yingyos Avihingsanon
Journal:  Int J Mol Sci       Date:  2019-10-08       Impact factor: 5.923

5.  A Study of IFN-α-Induced Chemokines CCL2, CXCL10 and CCL19 in Patients with Systemic Lupus Erythematosu.

Authors:  Mariela Gencheva Geneva-Popova; Stanislava Dimitrova Popova-Belova; Petya Nikolova Gardzheva; Krasimir Iliev Kraev
Journal:  Life (Basel)       Date:  2022-02-08

Review 6.  Diagnostic test accuracy of novel biomarkers for lupus nephritis-An overview of systematic reviews.

Authors:  Juliana de Andrade Rebouças Guimarães; Silvania da Conceição Furtado; Ana Cyra Dos Santos Lucas; Bruno Mori; José Fernando Marques Barcellos
Journal:  PLoS One       Date:  2022-10-10       Impact factor: 3.752

7.  Kallikrein-Kinin System Suppresses Type I Interferon Responses: A Novel Pathway of Interferon Regulation.

Authors:  Alecia Seliga; Michael Hweemoon Lee; Nicole C Fernandes; Viviana Zuluaga-Ramirez; Marta Didukh; Yuri Persidsky; Raghava Potula; Stefania Gallucci; Uma Sriram
Journal:  Front Immunol       Date:  2018-02-02       Impact factor: 7.561

Review 8.  Role of Chemokine (C-X-C Motif) Ligand 10 (CXCL10) in Renal Diseases.

Authors:  Jie Gao; Lingling Wu; Siyang Wang; Xiangmei Chen
Journal:  Mediators Inflamm       Date:  2020-02-05       Impact factor: 4.711

9.  Centrally Acting Angiotensin-Converting Enzyme Inhibitor Suppresses Type I Interferon Responses and Decreases Inflammation in the Periphery and the CNS in Lupus-Prone Mice.

Authors:  Cassandra Nocito; Cody Lubinsky; Michelle Hand; Sabeeya Khan; Tulsi Patel; Alecia Seliga; Malika Winfield; Viviana Zuluaga-Ramirez; Nicole Fernandes; Xiangdang Shi; Ellen M Unterwald; Yuri Persidsky; Uma Sriram
Journal:  Front Immunol       Date:  2020-09-15       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.